Jenburkt Pharmaceuticals News

Jenburkt Pharmaceuticals Q3FY26 Results

Jenburkt Pharmaceuticals reported Q3FY26 revenue of Rs 4302.39 lacs and net profit of Rs 593.14 lacs. Nine-month revenue reached Rs 12410.83 lacs with profit of Rs 2388.66 lacs.

Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026

Jenburkt Pharmaceuticals Limited announced its quarterly results for the quarter ended September 30, 2025. Revenue from operations increased to Rs 4,555.7 lacs compared to Rs 4,121.5 lacs in the same quarter last year, representing a 10.5% growth. Profit after tax rose to Rs 1,133.2 lacs from Rs 1,018.2 lacs year-over-year. For the half-year period, total revenue reached Rs 8,108.4 lacs versus Rs 7,375.16 lacs in the previous year. The company operates exclusively in the pharmaceuticals business segment. The Board meeting was held on October 28, 2025, where the Audit Committee recommended and the Board approved these unaudited financial results.

Jenburkt Pharmaceuticals Reports 5.1% Growth in Profit After Tax for Quarter Ended June 30, 2025

Jenburkt Pharmaceuticals Limited reported profit after tax of Rs. 779.18 lacs for the quarter ended June 30, 2025, compared to Rs. 741.60 lacs in the same quarter previous year. Revenue from operations increased to Rs. 3,552.68 lacs from Rs. 3,253.57 lacs year-over-year. Total comprehensive income reached Rs. 916.61 lacs versus Rs. 896.68 lacs in the corresponding quarter. Earnings per share stood at Rs. 17.66 compared to Rs. 16.80 in the same period last year. The company operates exclusively in the pharmaceuticals business segment. The board meeting was held on August 12, 2025, where the Audit Committee reviewed and the Board approved these standalone unaudited financial results.

Jenburkt Pharmaceuticals Reports Q4 Results and Recommends Dividend

Jenburkt Pharmaceuticals has announced its Q4 financial results and recommended a dividend. The company's Q4 revenue increased to 410.5 million rupees from 388 million rupees year-over-year. EBITDA rose to 108.6 million rupees from 98.5 million rupees, with the EBITDA margin improving to 26.45% from 24.37%. Net profit for Q4 grew to 85.4 million rupees from 79 million rupees in the previous year. The company has recommended a dividend of 18 rupees per equity share.